Skip to main content
Pharmaceutical Biology logoLink to Pharmaceutical Biology
. 2021 Dec 14;60(1):46–55. doi: 10.1080/13880209.2021.2010774

Efficacy of Yougui pill combined with Buzhong Yiqi decoction in alleviating the sexual dysfunction in female rats through modulation of the gut microbiota

Yangyun Wang 1, Chaoliang Shi 1, Wandong Yu 1, Wei Jiao 1, Guowei Shi 1,
PMCID: PMC8676705  PMID: 34904911

Abstract

Context

Yougui pill combined with Buzhong Yiqi decoction (YPBYD) is used to relieve sexual dysfunction in clinical practice.

Objective

To investigate changes in microbial composition caused by sexual dysfunction and identify dominant bacteria related to YPBYD treatment.

Materials and methods

Female Sprague-Dawley rats were randomly divided into four groups (n = 6): one group underwent Sham operation (Sham group), while three groups underwent ovariectomy (one model and two treatment groups). The ovariectomized (OVX) rats received oestradiol benzoate (250 µg/kg/week) or YPBYD (3.6 mL/d) via oral gavage for 4 weeks. Vaginal smear assay was performed; the serum levels of cyclic adenosine monophosphate (cAMP) and oestradiol (E2) were measured, followed by collection of stool samples for 16S rRNA sequencing.

Results

After YPBYD treatment, the levels of E2 and cAMP in OVX rats significantly increased (E2: from 20.45 ± 1.60 ng/L to 24.38 ± 1.70 ng/L; cAMP: from 261.41 ± 9.21 pg/mL to 373.75 ± 17.37 pg/mL). OVX treatment decreased diversity of gut microbiota and YPBYD treatment restored gut microbiota composition. Compared with Sham group, the abundance of Romboutsia significantly increased, while those of Proteobacteria and Staphylococcus markedly decreased in OVX group (all p < 0.05); meanwhile, the abundance of these microbes showed an opposite trend after YPBYD treatment. These microbiotas were involved in tyrosine and tryptophan biosynthesis and fatty acid metabolism.

Discussion and conclusions

These findings are the first to indicate YPBYD can alleviate female sexual dysfunction by modulating gut microbiota in OVX rats, which will help enhance the understanding on potential mechanism of YPBYD against sexual dysfunction.

Keywords: Sexual function, ovariectomized rat, traditional Chinese medicine, ELISA, 16S rRNA sequencing

Introduction

A human sexual response is the result of the complex interaction between biological and social psychological factors; sexual interaction is the physical manifestation of our need for acceptance and our need for life (Clayton and Valladares Juarez 2017). Therefore, sexual function plays an important role in improving an individual’s quality of life (QoL) and subjective well-being. However, the prevalence of sexual dysfunction in men and women increases with age (Stringer 2016). Dysfunction usually involves desire disorders, arousal disorder, dyspareunia and orgasmic disorder (McCabe et al. 2016). It has serious adverse effects on the QoL of patients and their sexual partners, such as marital discord, diminished self-esteem and psychological distress (Chung et al. 2015); hence, it is necessary to carry out an effective clinical treatment for sexual dysfunction.

Several synthetic medications (sildenafil and bremelanotide) (Berry and Berry 2013) are used in the management of male or female sexual dysfunction. However, these treatments are associated with some side effects (such as nausea, flushing and urinary tract infection) and economic problems (expensive cost) (Ohl et al. 2017; Simon et al. 2019). Based on these factors, traditional Chinese medicine (TCM) has attracted the attention of researchers as it is a natural form of medicine with fewer side effects, and can be made up of easily available properties (Chubak and Doctor 2018).

TCM has been used widely to treat sexual dysfunction in China for more than 2000 years, which significantly improves the sexual function of patients with sexual dysfunction (Chubak and Doctor 2018). TCM believes that the onset of sexual dysfunction is related to the imbalance of Yin-Yang in the kidney and liver, and is combined with Qi-deficiency and blood-stasis (Wei and Wei 2019). Thus, from the perspective of TCM, tonifying kidney, invigorating spleen and promoting blood circulation are the basic principles of sexual dysfunction treatment (Guo et al. 1999; Geng et al. 2019). Yougui pill and Buzhong Yiqi decoction are two important TCMs.

Among these, Yougui pill has been widely used to recuperate kidney-yang deficiency syndrome clinically for 400 years in China (Chen et al. 2019). Buzhong Yiqi decoction has the effects of raising Yang, removing blood stasis and strengthening the spleen and stomach (Lu et al. 2021). Taken together, Yougui pill combined with Buzhong Yiqi decoction (YPBYD), which consists of 17 traditional Chinese medical herbs, is effective in relieving sexual dysfunction in clinical practice (Liu et al. 2015; Wang 2015). Moreover, our previous study revealed the molecular mechanism of YPBYD in the treatment of sexual dysfunction from the perspective of network pharmacology (Wang et al. 2019). Research has indicated that the microbiota has many important functions, which can affect human development, physiology and emotion. The microbiota also communicates with the central nervous system, affecting brain function and behaviour (Mayer et al. 2015). Based on the relationship between microbiota and human diseases, Tirandaz et al. (2018) suggested that microbiota manipulation might be a potential treatment for sexual dysfunction via improving sexual behaviour. However, the direct evidence that YPBYD regulates the intestinal microbiota to improve the symptoms of sexual dysfunction is limited.

Hence, this study investigates the changes in the microbial composition caused by sexual dysfunction and identifies the dominant bacteria targeted by the YPBYD treatment. First, we established the sexual dysfunction model of female rat. Next, the oestrous cycle of rats was observed to evaluate whether the model was successfully constructed. Finally, the stool samples of rats were collected for 16S rRNA sequencing. This study will provide a theoretical basis for evaluating the efficacy of YPBYD in treating female sexual dysfunction through the regulation of the gut microbiota structure, and help researchers to further understand the interaction between the host and microorganisms during the treatment of sexual dysfunction.

Materials and methods

Animals

Eight-week-old female Sprague-Dawley rats (200 ± 20 g) were purchased from Shanghai Jihui Experimental Animal Feeding Co., Ltd. (Shanghai, China). All rats were maintained under standard laboratory conditions (18–22 °C) with 50–60% humidity for 1 week prior to the experiment, with ad libitum access to water and chow diet. This study was approved by the Animal Ethics Committee of Shanghai Fifth People’s Hospital, Fudan University, and all protocols were performed in accordance with the National Institutes of Health Guidelines for the Care and use of Laboratory Animals.

Preparation of YPBYD

YPBYD was composed of 17 different herbs, including Rehmannia glutinosa (the steamed and sun-dried tuber of Rehmannia glutinosa (Gaertn.) Libosch. ex Fisch. et Mey. [Scrophulariaceae], 24 g), Chinese yam (the dried root of Dioscorea opposita Thunb. [Dioscoreaceae], 30 g), Corni Fructus (the fruit of Cornus officinalis Sieb. et Zucc. [Cornaceae], 15 g), barbary wolfberry fruit (the fruit of Lycium chinense Miller (Solanaceae), 9 g), Dodder Seed (the seed of Cuscuta chinensis Lam. [Convolvulaceae], 12 g), deerhorn glue (the gelatine made from the horns of Cervus nippon Temminck [Cervidae], 12 g), Eucommia bark (the stem bark of Eucommia ulmoides Oliver [Eucommiaceae], 12 g), cinnamon (the bark of Cinnamomum cassia Presl (Lauraceae), 6 g), Chinese angelica (the root of Angelica sinensis (Oliv.) Diels [Umbelliferae], 9 g), aconite (the root of Aconitum carmichaeli Debx. [Ranunculaceae], 10 g), Radix Astragali (the dried root of Astragalus membranaceus (Fisch.) Bge. [Leguminosae], 18 g), liquorice (the root and rhizome of Glycyrrhiza uralensis Fisch. [Leguminosae], 9 g), ginseng (the fleshy root of Panax ginseng C. A. Meyer [Araliaceae], 6 g), orange peel (the peel of Citrus reticulata Blanco [Rutaceae], 6 g), Morinda root (the root of Morinda officinalis How. [Rubiaceae], 15 g), Atractylodes (the rhizomes of Atractylodes lancea (Thunb.) DC. [Compositae], 9 g) and Herba Epimedii (the aerial part of Epimedium brevicornum Maxim. [Berberidaceae], 15 g). The YPBYD solution was prepared as follows: dried Chinese medicinal materials were soaked in 800 mL of water for 30 min and then boiled for 30 min to obtain the concentrated YPBYD potion.

OVX model construction and treatment

All rats were randomly divided into four groups (six rats per group): Sham group, ovariectomized (OVX) group, OVX treated with oestradiol benzoate group (OVX + EB) and OVX treated with YPBYD group (OVX + YPBYD). The approach of model construction was described previously (Xu et al. 2019). In brief, the rats in each group were anaesthetized by intraperitoneal injection of 1% pentobarbital sodium (40 mg/kg). In the Sham group, a longitudinal incision was made on the abdominal wall of the rats, and the fat around the ovary was removed. In OVX rats, bilateral ovaries were excised through the longitudinal incision. Within four days after surgery, the rats in the OVX + EB group were subcutaneously injected with 250 µg/kg of EB once a week. Seven days after surgery, the rats in the OVX + YPBYD group were administered with 3.6 mL of YPBYD via oral gavage once a day for four consecutive weeks. The dose was calculated based on the ratio of human and animal body surface area with a coefficient of 0.018. The rats in the Sham and OVX groups were injected with the same amount of vegetable oil. After treatment for 4 weeks, all animals were euthanized. The blood samples were collected before the rats died. Meanwhile, the stool samples were collected for subsequent experiments.

Vaginal smear assay

Vaginal smears were taken on the 5th day after surgery (once a day for five consecutive days) to observe the characteristics of vaginal cell changes during the oestrus cycle in each group. The vaginal contents were collected using a cotton swab moistened with normal saline by inserting the tip into the rat vagina within 0.5 cm, and then the vaginal fluid was evenly spread on the glass slide. After natural drying, the slides were fixed in 10% formalin solution for 10 min and stained with Giemsa solution for 10 min. Next, the morphology of vaginal cells was observed under a microscope. Notably, three types of cells were detected on the vaginal smears: keratinocytes (polygonal cells without nucleus); leukocytes (small and round cells); and epithelial cells (round nucleated cells). The stage of the oestrus cycle was determined based on the ratio of these cells. Specifically, the oestrus cycle of rats is four days and is divided into five stages: pro-oestrus, oestrus, metoestrus I, metoestrus II and dioestrus.

Enzyme-linked immunosorbent assay

Blood was collected from the abdominal aorta of rats and then centrifugation at 1600×g for 15 min at 4 °C to obtain serum samples. The concentration of oestradiol (E2) and cyclic adenosine monophosphate (cAMP) was measured by enzyme-linked immunosorbent assay (ELISA) kits (E2: CGE20048, Shanghai Chen Gong Biotechnology Co., Ltd., Shanghai, China; cAMP: B20344, Jianglaibio Co., Ltd., Shanghai, China) according to the manufacturer’s protocol.

Bacterial DNA extraction and 16S rRNA sequencing

The total bacterial DNA was extracted from the stool samples of each rat using the cetyl trimethyl ammonium bromide/sodium dodecyl sulphate (CTAB/SDS) method. The purity and concentration of DNA were detected utilizing a NanoDrop 2000 spectrophotometer, while the DNA integrity was detected by 1% agarose gels. DNA with A260/A280 ratio between 1.8 and 2.0 was considered qualified. 16S rRNA sequencing was performed as previously described (Wu et al. 2016). In brief, the V3–V4 region of the 16S rRNA gene was amplified by polymerase chain reaction with 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTWTCTAAT) primers. Then, the libraries were generated and sequenced on an Illumina HiSeq2500 platform. Finally, 250 bp paired-end reads were obtained.

Analysis of sequenced data

After sequencing, the paired raw data were merged using Trimmomatic (Bolger et al. 2014). Quality control of raw data was performed; then, the data were filtered into clean reads using the Quantitative Insights Into Microbial Ecology software (http://qiime.org/). Based on the similarity level, the sequences were divided into different operational taxonomic units (OTUs); OTUs with ≥97% similarity level were selected for bioinformatics analysis using USEARCH (version 7.1, http://drive5.com/uparse/). Taxonomic analysis of OTUs with a similarity level of greater than 97% was performed using RDP classifier (http://sourceforge.net/projects/rdp-classifier/) to obtain the community composition of each sample. The rank abundance curve and rarefaction curve were plotted to determine the species abundance and species uniformity.

Diversity analysis

Next, alpha-diversity indexes including ACE, Chao, Shannon and Simpson were calculated to access the richness and diversity of species. The beta-diversity was also analysed to display the similarity of gut bacteria composition between different samples. Results were visualized using principal component analysis (PCA), principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS).

Differential abundance analysis and function prediction

To identify the altered microbiotas related to OVX and drug treatment, the differential abundance analysis of microbes was performed. The Kruskal–Wallis (KW) rank sum test is a method used to perform a non-parametric test of multi-group independent samples, which can analyse the significant difference of species in multiple groups and calculate the false discovery rate q value for the p value (Guo et al. 2013). In this analysis, we used KW rank sum test to evaluate the differential abundance among the four groups. Moreover, linear discriminant analysis effect size (LEfSe) (Segata et al. 2011) was applied to determine the microbiotas that could best represent the characteristics of each group; then, a linear discriminant analysis (LDA) was used to estimate the impact of the abundance of each microbe on the different effect. The taxa with a higher LDA score indicated a higher consistency; the taxa with an LDA score of >2 and a p value of <0.05 were considered significant. Furthermore, phylogenetic investigation of communities by reconstruction of unobserved states (PICRUst) (Douglas et al. 2018) was used to predict the functional enrichment of different microbes.

Statistical analysis

All data were expressed as mean ± standard deviation and were analysed using one-way analysis of variance. Statistical analysis was performed using GraphPad prism 5 (GraphPad Software, San Diego, CA). A p value of less than 0.05 was considered significant.

Results

Effect of YPBYD on the oestrus cycle

To verify whether the model was successfully constructed, we observed the oestrous cycle of rats in each group. Most of the cell types in the oestrous dioestrus state were leukocytes, those in the pro-oestrus state were epithelial cells, those in the oestrus state were keratinocytes, and those in the late oestrus state were keratinized cells and leukocytes. As shown in Figure 1, the rats in the Sham group showed a complete oestrus cycle. The vaginal epithelial cells of rats in the OVX group were always composed of leukocytes, indicating that the rats were in constant dioestrum. Notably, the vaginal cells of OVX rats treated with EB or YPBYD were keratinized after about 3 and 2 days of treatment, respectively, which indicated that the treated OVX rats gradually entered the oestrus state. These results revealed that the YPBYD treatment had a certain therapeutic effect on sexual dysfunction in rats.

Figure 1.

Figure 1.

Effect of YPBYD treatment on the oestrous cycle of rats in each group. Representative images of vaginal epithelium cells taken under ×200 magnification. The nucleus is stained purple or blue purple, and the cytoplasm is stained pink.

Effect of YPBYD on the serum levels of cAMP and E2

Compared with the rats in the Sham group (299.39 ± 22.40 pg/mL), those in the OVX group had lower serum levels of cAMP (261.40 ± 9.21 pg/mL, p < 0.01). After treatment with EB or YPBYD, the level of cAMP in rats significantly increased compared with that in the OVX group (EB: 301.91 ± 25.68 pg/mL, p < 0.05; YPBYD: 373.75 ± 17.37 pg/mL, p < 0.01, Figure 2(A)). In addition, the level of E2 in the OVX group was significantly decreased compared with that in the Sham group (20.45 ± 1.61 ng/L vs. 26.38 ± 1.61 ng/L, p < 0.01). After the 4-week treatment, the serum level of E2 in OVX rats returned to normal (EB: 25.05 ± 1.79 ng/L, p < 0.01; YPBYD: 24.38 ± 1.71 ng/L, p < 0.01, Figure 2(B)).

Figure 2.

Figure 2.

Effect of YPBYD treatment on the levels of cyclic adenosine monophosphate (cAMP) and oestradiol (E2). (A) Serum levels of cAMP from rats. (B) Serum levels of E2 from rats. Data analysis between two groups was performed using ANOVA and the Newman–Keuls multiple comparison test. **p < 0.01 compared with Sham group, #p < 0.05 and ##p < 0.01 compared with OVX group.

Overview of 16S rRNA sequencing data

To explore the effect of YPBYD on the gut microbiota of OVX rats, the stool samples were collected for 16S rRNA sequencing. A total of 959,204 sequences and 397,208,516 bases were obtained from the 24 stool samples. The average length of the sequences was 414 bp, and the results of each sample are presented in Table 1.

Table 1.

16S rRNA sequencing results of each sample.

Sample Seq_num Base_num Mean_length Min_length Max_length
C1 42543 17825261 418.994 219 489
C2 36988 15367284 415.4667 317 432
C3 38225 16066226 420.3068 211 432
C4 42650 17694270 414.8715 283 506
C5 40353 16776944 415.7546 252 489
C6 36462 15104378 414.2498 363 441
C_1_1 36704 15280979 416.3301 233 432
C_1_2 40812 16844325 412.7297 277 433
C_1_3 37852 15574626 411.4611 293 433
C_1_4 39222 16163179 412.0947 254 480
C_1_5 49592 20283219 409.0018 252 447
C_1_6 37266 15446380 414.4899 291 431
C_1 36054 15052339 417.4943 265 440
C_2 39839 16627037 417.3558 317 477
C_3 38436 16001795 416.3231 270 433
C_4 34516 14304805 414.4398 292 434
C_5 43189 17736398 410.6693 233 434
C_6 39419 16053294 407.2476 317 434
T1 40411 16819390 416.2082 245 442
T2 39069 16035045 410.4289 232 443
T3 44067 18082153 410.3332 277 455
T4 46018 19078368 414.5849 254 443
T5 40387 16896128 418.3556 300 489
T6 39130 16094693 411.3134 259 489

C1-6: Sham group; C_1_1-6: OVX group; C_1-6: OVX + EB group; T1-6: OVX + YPBYD.

Analysis of microbiota diversity and community composition

The rank abundance curve and rarefaction curve showed a flattening trend, indicating that the species distribution was uniform and the sequencing data were large enough to reflect the majority of microbial diversity information in the samples (Figure 3). Next, the alpha and beta diversity analyses were conducted. Ace and Chao indexes were used to estimate the richness of species, while Simpson and Shannon indexes were used to assess the diversity of microbes. Compared with the Sham group, the Ace, Chao and Shannon indexes of the OVX group were significantly lower (p < 0.05, Figure 4(A–C)), while the Simpson index was significantly higher (p < 0.05, Figure 4(D)). These results revealed that the OVX group had lower richness and microbial diversity than the Sham group. Meanwhile, the diversity of microbiota slightly improved after EB or YPBYD treatment, indicating that YPBYD could relieve the dysregulation of intestinal flora. In addition, the beta diversity (PCA, PCoA and NMDS plots) showed that the sample in each group had obvious clustering and the bacterial structure of the Sham and OVX groups was obviously separated (Figure 5(A–C)).

Figure 3.

Figure 3.

Rank abundance curve and rarefaction curve of the 16S rRNA sequencing data. Red represents the Sham group, blue represents the OVX group, green represents the OVX + EB group and yellow represents the OVX + YPBYD group.

Figure 4.

Figure 4.

Alpha diversity analysis of gut microbial community structure in each group. (A) Ace index. (B) Chao index. (C) Shannon index. (D) Simpson index. Red represents the Sham group, blue represents the OVX group, green represents the OVX + EB group and yellow represents the OVX + YPBYD group. *p < 0.05, **p < 0.01 and ***p < 0.001.

Figure 5.

Figure 5.

Beta diversity analysis of gut microbial community structure in each group. (A) PCA plot. (B) PCoA plot. (C) NMDS plot. Red represents the Sham group, blue represents the OVX group, green represents the OVX + EB group and yellow represents the OVX + YPBYD group.

Furthermore, the gut microbial composition at phylum and genus levels was analysed to observe the alterations in bacteria caused by YPBYD treatment. In brief, at the phylum level (Figure 6(A)), Firmicutes, Actinobacteriota, Desulfobacterota and Proteobacteria were the three dominant phyla in these four groups. In brief, the abundance levels of Firmicutes in Sham, OVX, OVX + EB and OVX + YPBYD groups were 93.19%, 92.57%, 81.91% and 85.78%, respectively. The abundance level of Actinobacteriota in the OVX group (2.87%) was lower than that in the Sham group (4.60%), and the relative abundance of it increased to 3.33% after YPBYD treatment. Compared with the Sham group (0.69%), the abundance level of Desulfobacterota in the OVX group increased (1.88%); meanwhile, the abundance level of Desulfobacterota decreased in the OVX + YPBYD group (0.55%) compared with that in the OVX group. In addition, the abundance level of Proteobacteria decreased in the OVX group (0.20%) compared with that in the Sham group (0.44%); by contrast, the abundance level of Proteobacteria increased after YPBYD treatment (8.10%).

Figure 6.

Figure 6.

Effect of YPBYD treatment on the gut microbial composition of rats. (A) Bacterial composition of the gut microbiotas at the phylum level. (B) Bacterial composition of the gut microbiotas at the genus level. The different coloured columns represent different species, while the length of the columns represents the size of the species.

At the genus level, Romboutsia, Lactobacillus and Staphylococcus were predominant genera in these groups (Figure 6(B)). Results revealed that the abundance levels of both Romboutsia and Lactobacillus in the OVX group were greater than those in the Sham group. Following the YPBYD treatment, the abundance levels of Romboutsia and Lactobacillus were lower in the OVX + YPBYD group than in the OVX group. Meanwhile, the abundance level of Staphylococcus decreased in the OVX group compared with that in the Sham group; by contrast, the abundance level of Staphylococcus increased in the OVX + YPBYD group compared with that in the OVX group. These results suggested that YPBYD might play a therapeutic role by partially restoring the dysfunctional gut microbiota.

Results of differential analysis of gut microbiota altered by YPBYD treatment

To further screen the significant differences in the gut microbiotas altered by YPBYD treatment, differential analysis and LEfSe analysis were conducted. As shown in Figure 7, several significantly changed phyla, such as Proteobacteria, Deferribacterota and Campilobacterota (Figure 7(A)), as well as some significant altered genera, such as Romboutsia, Staphylococcus, Jeotgalicoccus and Corynebacterium (Figure 7(B)), were identified. We observed that the abundance levels of Proteobacteria as well as those of Staphylococcus, Jeotgalicoccus and Corynebacterium was decreased in the OVX group compared with that in the Sham group, while the abundance levels of these microbes increased in the treatment groups (OVX + EB and OVX + YPBYD). In addition, the abundance level of Romboutsia was significantly increased in the OVX group compared with that in the Sham group, and the abundance level of Romboutsia obviously decreased in the OVX + YPBYD group compared with that in the OVX group.

Figure 7.

Figure 7.

Differential analysis of gut microbiotas altered by YPBYD treatment. *p < 0.05, **p < 0.01.

Furthermore, 359 taxa among these four groups were identified using LEfSe analysis (Figure 8), and the LDA scores ranged from 0.0 to 5.5. Results indicated that the dominant bacteria in the Sham group were f_Staphylococcaceae and g_Staphylococcus; those in the OVX group were f_Peptostreptococcaceae and o_Peptostreptococcales_Tissierellales; those in the OVX + EB group were dominated by s_Lactobacillus_reuteri and g_Enterococcus; and those in the OVX + YPBYD group were f_Clostridiaceae and o_Clostridiales.

Figure 8.

Figure 8.

Linear discriminant analysis effect size cladograms for the comparisons of the four study groups. Red represents the Sham group, blue represents the OVX group, green represents the OVX + EB group and pink represents the OVX + YPBYD group.

Results of predicted microbial function

We determined the KEGG pathway involved in the microbiota function using PICRUst. A total of 50 KEGG pathways, which were divided into six categories (metabolism, generic information processing, environmental information processing, cellular processes, human diseases and organismal systems) were identified. As shown in Figure 6, the microbes related to YPBYD treatment were mainly enriched in the biosynthesis of amino acids, pyruvate metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, fatty acid metabolism and citrate cycle (Figure 9).

Figure 9.

Figure 9.

Microbial community function was predicted by PICRUst.

Discussion

Sexual function depends on the complex interaction of physical, psychosocial and neurobiological factors. It may be affected centrally (brain) or peripherally (genitals) or both, and may affect any or all stages of the sexual response cycle (Clayton and Valladares Juarez 2017). The balance between excitatory and inhibitory neuromodulation process is thought to produce specific sexual responses. It is believed that sexual dysfunction is due to overactive inhibition, overactive excitement or a combination of both (Faubion and Rullo 2015). Accumulated evidence indicates that gut microbiota can modulate neurotransmitter and plays roles in the development and impairment of the central nervous system (Strandwitz 2018). Thus, it is necessary to explore the role of intestinal microbiotas in the pathogenesis of sexual dysfunction and to screen the microbe with potential therapeutic effects in this disease. In the present study, we explored the changes in gut microbiota of female rat model with sexual dysfunction. Results showed that the serum levels of cAMP and E2 in OVX rats were significantly decreased compared with those in Sham rats; meanwhile, the levels of these indexes were markedly increased after EB and YPBYD treatment. The relative abundance of microbes such as Proteobacteria, Romboutsia and Staphylococcus was significantly changed in the OVX rats during the period of YPBYD treatment.

Results of the vaginal smear showed that the OVX rats did not have a complete oestrus cycle, and most of the vaginal epithelial cells were leukocytes, indicating that the rats were in the dioestrus state. These findings indicated that the model of sexual dysfunction was successfully constructed. Moreover, ELISA result revealed that the level of E2 in the OVX group was lower than that in the Sham group. E2 is implicated as one of the steroids important for modulating the sexual desire of women and is crucial to the sexual motivation and arousal of women (Rao et al. 2015). Previous study found that oestrogen therapy could increase the postmenopausal women’s sexual desire by producing periovulatory levels of circulating E2 (Cappelletti and Wallen 2016). In addition, the use of hormonal contraceptives reduced the neural response of women to sexual stimulation by decreasing the level of several hormones such as E2, which could possibly lead to sexual dysfunction (Casado-Espada et al. 2019). These studies highlighted the important regulatory role of E2 in sexual response. In this experiment, the level of E2 in OVX rats was increased after YPBYD treatment; staining results showed that the YPBYD-treated OVX rats gradually entered the oestrus state, which further confirmed that YPBYD treatment improved the symptoms of sexual dysfunction.

Sexual dysfunction can adversely affect the QoL, self-esteem and interpersonal relationships, and may lead to psychopathological disorders (Jaafarpour et al. 2013). Meanwhile, eating disorders are closely related to the occurrence of sexual dysfunction (Castellini et al. 2019). To our knowledge, the underlying relationship between microbes and psychopathological state as well as dietary habit has been recognized (Rinninella et al. 2019). Thus, we explored the direct association between gut microbiota and sexual dysfunction (Bersani et al. 2020). Our results showed that the species evenness and richness was significantly decreased in the OVX group than in the Sham group; meanwhile, YPBYD treatment markedly enhanced the richness and diversity of gut microbiota in OVX rats, indicating that YPBYD had the ability to restore the structure of the dysfunctional intestinal microbiota. Notably, we observed that the abundance levels of Proteobacteria and Staphylococcus in the OVX group were lower than those in the Sham group; however, YPBYD treatment could restore these changes. Previous study indicated that the abundance level of Proteobacteria decreased in the OVX mice, which was associated with their susceptibility to metabolic syndrome (MS) and metabolic endotoxaemia (Kaliannan et al. 2018). Di Francesco et al. (2019) reported that MS was closely linked to female sexual dysfunctions, such as sexual desire disorder, orgasm disorder and decreased satisfaction. A previous study on Staphylococcus indicated that Staphylococcus aureus induced an increase in the levels of prostaglandin E(2) [PGE92)] in the hypothalamus (Martins et al. 2012), and the hypothalamus and limbic systems were involved in sexual arousal (Harsh and Clayton 2018). Moreover, PGE(2) might be used as a novel strategy for the treatment of erectile dysfunction (El Melegy et al. 2005), and PGE(2) could serve a crucial role in improving sexual pain caused by endometriosis (Peng et al. 2018). These studies emphasized that these microbiotas were indirectly linked to the occurrence of sexual dysfunction, and YPBYD treatment might provide therapeutic effects by altering the abundance of these microbes. Furthermore, the relative abundance of Romboutsia was significantly changed after YPBYD treatment, which also attracted our attention. Zeng et al. (2019) demonstrated that several microbes such as Romboutsia were positively correlated with body weight and serum lipids, which might be considered as gut microbiota markers for obesity-related metabolic abnormalities. Obesity could increase the risk of erectile dysfunction in men and the prevalence of sexual dysfunction in women (Esposito et al. 2008). Taken together, Romboutsia might play a role in the pathogenesis of sexual dysfunction.

We also predicted the function of identified microbiotas, and results showed that microbes were significantly involved in tyrosine and tryptophan biosynthesis as well as fatty acid metabolism. Tyrosine kinases had beneficial effects on erection and sexual function (Holland et al. 2017). Meanwhile, tryptophan had the ability to improve the sexual quality in patients with premature ejaculation (Sansalone et al. 2016). In addition, disturbed fatty acid metabolism might be regarded as a potential marker of vasculogenic erectile dysfunction (Ben Khedher et al. 2017). Thus, we speculated that these functions might also serve important roles in the occurrence of female sexual dysfunction.

This study is the first to explore the mechanism of YPBYD treatment, suggesting that YPBYD can improve the symptoms of sexual dysfunction, possibly by modulating the gut microbiota in OVX rats. However, there are some limitations in this study. First, our research has incomplete data. The study is only conducted in female rats with sexual dysfunction, and male rats are not included. Second, the specific association between these identified microbiotas and sexual dysfunction-related clinical characteristics has not been investigated. Finally, the gut microbiota of rats is different from those of human, so whether these screened microbes play a role in human sexual dysfunction needs to be further investigated. Therefore, a follow-up study is warranted to assess whether the obtained microbes could be used as markers and therapeutic targets of sexual dysfunction.

Conclusions

This study is the first to provide evidence confirming that intestinal microbiotas play a key role in the pathogenesis and YPBYD treatment of sexual dysfunction. Results showed that sexual dysfunction caused by ovariectomy could lead to the changes in the diversity and structure of intestinal microbiota in rats, and YPBYD treatment could partially reverse these alterations. OVX rats had a higher abundance of Romboutsia and lower abundance of Proteobacteria and Staphylococcus compared with Sham group; meanwhile, YPBYD treatment could decrease the level of Romboutsia and increase the abundance of Proteobacteria and Staphylococcus. Moreover, YPBYD influenced the KEGG pathways such as tyrosine and tryptophan biosynthesis as well as fatty acid metabolism. Together, these findings indicated that the effects of YPBYD on female sexual dysfunction might depend on its regulation of gut microbiota.

Author contributions

Conception and research design: Yangyun Wang and Guowei Shi; acquisition of data: Chaoliang Shi, Wandong Yu and Wei Jiao; analysis and interpretation of data: Chaoliang Shi, Wandong Yu and Wei Jiao; statistical analysis: Chaoliang Shi, Wandong Yu and Wei Jiao; obtaining funding: Guowei Shi; drafting the manuscript: Yangyun Wang; revision of the manuscript for important intellectual content: Guowei Shi. All authors read and approved the final manuscript.

Funding Statement

This work was supported by the Shanghai Key Medical Specialty Program [Grant Number: ZK2019A03], Scientific Research Project of Shanghai Municipal Health and Family Planning Commission [Grant Number: 201940006] and Hospital-level Project of Shanghai Fifth People’s Hospital [Grant Number: 2019WYZT02].

Disclosure statement

The authors declare that they have no competing interests.

Data availability statement

All data generated or analysed during this study are included in this published article.

References

  1. Ben Khedher MR, Bouhajja H, Haj Ahmed S, Abid M, Jamoussi K, Hammami M.. 2017. Role of disturbed fatty acids metabolism in the pathophysiology of diabetic erectile dysfunction. Lipids Health Dis. 16:241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry MD, Berry PD.. 2013. Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model. J Sex Med. 10(11):2627–2643. [DOI] [PubMed] [Google Scholar]
  3. Bersani FS, Mellon SH, Lindqvist D, Kang JI, Rampersaud R, Somvanshi PR, Doyle FJ, Hammamieh R, Jett M, Yehuda R, et al. 2020. Novel pharmacological targets for combat PTSD-metabolism, inflammation, the gut microbiome, and mitochondrial dysfunction. Mil Med. 185(Suppl. 1):311–318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bolger AM, Lohse M, Usadel B.. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 30(15):2114–2120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cappelletti M, Wallen K.. 2016. Increasing women’s sexual desire: the comparative effectiveness of estrogens and androgens. Horm Behav. 78:178–193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo ÁL.. 2019. Hormonal contraceptives, female sexual dysfunction, and managing strategies: a review. J Clin Med. 8(6):908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Castellini G, Lelli L, Cassioli E, Ricca V.. 2019. Relationships between eating disorder psychopathology, sexual hormones and sexual behaviours. Mol Cell Endocrinol. 497:110429. [DOI] [PubMed] [Google Scholar]
  8. Chen R, Wang J, Zhan R, Zhang L, Wang X.. 2019. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill. J Ethnopharmacol. 244:112139. [DOI] [PubMed] [Google Scholar]
  9. Chubak B, Doctor A.. 2018. Traditional Chinese medicine for sexual dysfunction: review of the evidence. Sex Med Rev. 6(3):410–418. [DOI] [PubMed] [Google Scholar]
  10. Chung E, Gilbert B, Perera M, Roberts MJ.. 2015. Premature ejaculation: a clinical review for the general physician. Aust Fam Physician. 44(10):737–743. [PubMed] [Google Scholar]
  11. Clayton AH, Valladares Juarez EM.. 2017. Female sexual dysfunction. Psychiatr Clin North Am. 40(2):267–284. [DOI] [PubMed] [Google Scholar]
  12. Di Francesco S, Caruso M, Robuffo I, Militello A, Toniato E.. 2019. The impact of metabolic syndrome and its components on female sexual dysfunction: a narrative mini-review. Curr Urol. 12(2):57–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Douglas GM, Beiko RG, Langille MGI.. 2018. Predicting the functional potential of the microbiome from marker genes using PICRUSt. Methods Mol Biol. 1849:169–177. [DOI] [PubMed] [Google Scholar]
  14. El Melegy NT, Ali ME, Awad EM.. 2005. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int. 96(7):1079–1086. [DOI] [PubMed] [Google Scholar]
  15. Esposito K, Giugliano F, Ciotola M, De Sio M, D’Armiento M, Giugliano D.. 2008. Obesity and sexual dysfunction, male and female. Int J Impot Res. 20(4):358–365. [DOI] [PubMed] [Google Scholar]
  16. Faubion SS, Rullo JE.. 2015. Sexual dysfunction in women: a practical approach. Am Fam Physician. 92(4):281–288. [PubMed] [Google Scholar]
  17. Geng Q, Fu Q, Zhang C, Guo J, Zhao Y, Wang F, Li Z.. 2019. Huanshao capsules for erectile dysfunction with spleen and kidney deficiency: a multicentered clinical trial. Natl J Androl. 25:730–733. [PubMed] [Google Scholar]
  18. Guo J, Kong L, Gao X, Lu J, Pang J.. 1999. A parallel study on the effects in treatment of impotence by tonifying the kidney with and that without improving blood circulation. J Tradit Chin Med. 19:123–125. [PubMed] [Google Scholar]
  19. Guo S, Zhong S, Zhang A.. 2013. Privacy-preserving Kruskal–Wallis test. Comput Methods Prog Biomed. 112(1):135–145. [DOI] [PubMed] [Google Scholar]
  20. Harsh V, Clayton AH.. 2018. Sex differences in the treatment of sexual dysfunction. Curr Psychiatry Rep. 20(3):18. [DOI] [PubMed] [Google Scholar]
  21. Holland BC, Shetty Z, Alanee S.. 2017. The effect of targeted therapy for genitourinary malignancies on sexual function and fertility. Curr Urol Rep. 18(8):65. [DOI] [PubMed] [Google Scholar]
  22. Jaafarpour M, Khani A, Khajavikhan J, Suhrabi Z.. 2013. Female sexual dysfunction: prevalence and risk factors. J Clin Diagn Res. 7:2877–2880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kaliannan K, Robertson RC, Murphy K, Stanton C, Kang C, Wang B, Hao L, Bhan AK, Kang JX.. 2018. Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice. Microbiome. 6(1):205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Liu T, Liu GL, Yang HJ.. 2015. The clinical effect of Guipi decoction and Yougui pill in the treatment of male sexual dysfunction. Chin Med Mod Dist Educ China. 13:56–57. [Google Scholar]
  25. Lu B, Du J, Wu X.. 2021. The effects of modified Buzhong Yiqi decoction combined with Gangtai ointment on the wound healing and anal function in circumferential mixed hemorrhoid patients. Am J Transl Res. 13:8294–8301. [PMC free article] [PubMed] [Google Scholar]
  26. Martins JM, Longhi-Balbinot DT, Soares DM, Figueiredo MJ, Malvar DdC, de Melo MCC, Rae GA, Souza GEP.. 2012. Involvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats. J Appl Physiol. 113(9):1456–1465. [DOI] [PubMed] [Google Scholar]
  27. Mayer EA, Tillisch K, Gupta A.. 2015. Gut/brain axis and the microbiota. J Clin Invest. 125(3):926–938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Lewis R, Segraves RT.. 2016. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 13(2):135–143. [DOI] [PubMed] [Google Scholar]
  29. Ohl DA, Carlsson M, Stecher VJ, Rippon GA.. 2017. Efficacy and safety of sildenafil in men with sexual dysfunction and spinal cord injury. Sex Med Rev. 5(4):521–528. [DOI] [PubMed] [Google Scholar]
  30. Peng B, Zhan H, Alotaibi F, Alkusayer GM, Bedaiwy MA, Yong PJ.. 2018. Nerve growth factor is associated with sexual pain in women with endometriosis. Reprod Sci. 25(4):540–549. [DOI] [PubMed] [Google Scholar]
  31. Rao A, Steels E, Beccaria G, Inder WJ, Vitetta L.. 2015. Influence of a specialized Trigonella foenum-graecum seed extract (Libifem), on testosterone, estradiol and sexual function in healthy menstruating women, a randomised placebo controlled study. Phytother Res. 29(8):1123–1130. [DOI] [PubMed] [Google Scholar]
  32. Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, Miggiano GAD, Gasbarrini A, Mele MC.. 2019. Food components and dietary habits: keys for a healthy gut microbiota composition. Nutrients. 11:2393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sansalone S, Russo GI, Mondaini N, Cantiello F, Antonini G, Cai T.. 2016. A combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts is able to improve sexual quality of life in patient with premature ejaculation. Arch Ital Urol Androl. 88(3):171–176. [DOI] [PubMed] [Google Scholar]
  34. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C.. 2011. Metagenomic biomarker discovery and explanation. Genome Biol. 12(6):R60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH.. 2019. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 134(5):909–917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Strandwitz P. 2018. Neurotransmitter modulation by the gut microbiota. Brain Res. 1693(Pt B):128–133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Stringer JD. 2016. Gender and sexual health: sexual dysfunction. FP Essent. 449:18–26. [PubMed] [Google Scholar]
  38. Tirandaz H, Ebrahim-Habibi MB, Moradveisi B, Raoofi S, Salehi-Najafabadi A, Mohammadi E.. 2018. Microbiota potential for the treatment of sexual dysfunction. Med Hypotheses. 115:46–49. [DOI] [PubMed] [Google Scholar]
  39. Wang JJ. 2015. To the spleen decoction and right to pill treatment of 50 cases of male sexual dysfunction. World Latest Med Informat. 15:146. [Google Scholar]
  40. Wang Y, Yu W, Shi C, Jiao W, Li J, Ge J, Hong Y, Shi G.. 2019. Network pharmacology of Yougui pill combined with Buzhong Yiqi decoction for the treatment of sexual dysfunction. Evid Based Complement Alternat Med. 2019:1243743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wei G, Wei T.. 2019. New progress in the treatment of sexual dysfunction by syndrome differentiation of TCM. World Latest Med Informat. 19:197–228. [Google Scholar]
  42. Wu X, Zhang H, Chen J, Shang S, Wei Q, Yan J, Tu X.. 2016. Comparison of the fecal microbiota of dholes high-throughput Illumina sequencing of the V3-V4 region of the 16S rRNA gene. Appl Microbiol Biotechnol. 100(8):3577–3586. [DOI] [PubMed] [Google Scholar]
  43. Xu Y, Li X, Chen T, Qu YK, Zheng HX, Zhang ZJ, Zhao Y, Lin N.. 2019. Radix Paeoniae Alba increases serum estrogen level and up-regulates estrogen receptor expression in uterus and vagina of immature/ovariectomized mice. Phytother Res. 33(1):117–129. [DOI] [PubMed] [Google Scholar]
  44. Zeng Q, Li D, He Y, Li Y, Yang Z, Zhao X, Liu Y, Wang Y, Sun J, Feng X, et al. 2019. Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities. Sci Rep. 9(1):13424. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data generated or analysed during this study are included in this published article.


Articles from Pharmaceutical Biology are provided here courtesy of Taylor & Francis

RESOURCES